BioNexus signs CogniAI healthcare licence with RYET, paying 560,000 shares (~16% stake)

BioNexus Gene Lab Corp

BGLC to issue 410,000 shares for stated US$3.5M licence consideration plus 150,000 shares for 500,000 RYET ordinary shares; 560,000 total, ~16.0% of post-issuance shares.
Ten-year exclusive Malaysian healthcare licence with two five-year renewals; RYET gets 10% royalty on technology receipts collected, with no minimum royalty or annual platform fee.
Closing pending: RYET must deliver technology by December 4, 2026; acceptance testing, due diligence and approvals required, with termination possible if no closing by March 31, 2027.
Malaysia raised public healthcare digitalization allocation to RM1 billion covering 150 hospitals and 2,000+ clinics; MOH targets electronic medical records nationwide by 2029.
BGLC has not been awarded any government contract, and public-sector work depends on government procurement; RYET reported ~US$1.73M contracted CogniAI activity in June 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.